14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CAPR vs ENTA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CAPR Overall Winner
6-Pillar Tally: CAPR 3 – 2 ENTA (1 Tie)
Matrix Metrics: CAPR 5 – 5 ENTA
As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.45 (78.7x Forward P/E, 0.0% operating margin), whereas ENTA carries 46.2/100 (HOLD) at $10.79 (44.0x Forward P/E, -90.0% operating margin).
Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -90.0% operating margin) and revenue trajectory (-7.9% vs. -21.6% YoY).
Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
ENTA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $326.2M market capitalization and -90.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CAPR vs ENTA Key Questions & Quantitative Answers
As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.45 (78.7x Forward P/E, 0.0% operating margin), whereas ENTA carries 46.2/100 (HOLD) at $10.79 (44.0x Forward P/E, -90.0% operating margin). Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -90.0% operating margin) and revenue trajectory (-7.9% vs. -21.6% YoY). Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CAPR leads the Growth & Scale pillar: CAPR posts -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin), compared with ENTA at -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CAPR cumulative revenue shifted -33.3% while ENTA shifted -66.7%. In operating R&D and SG&A reinvestment, CAPR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTA.
ENTA screens cheaper on headline valuation multiples. CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin), whereas ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAPR (-100.5% ROE) versus ENTA (-70.1% ROE) capital efficiency.
In options market volatility and institutional positioning, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.50β · 151% Vol realized risk). By comparison, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.